Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Cash, Cash Equivalents, Marketable Securities : $3.79 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings Cash, Cash Equivalents, Marketable Securities?

Sonnet BioTherapeutics Holdings's quarterly cash, cash equivalents, marketable securities increased from Sep. 2023 ($2.27 Mil) to Dec. 2023 ($3.02 Mil) and increased from Dec. 2023 ($3.02 Mil) to Mar. 2024 ($3.79 Mil).

Sonnet BioTherapeutics Holdings's annual cash, cash equivalents, marketable securities declined from Sep. 2021 ($27.62 Mil) to Sep. 2022 ($3.05 Mil) and declined from Sep. 2022 ($3.05 Mil) to Sep. 2023 ($2.27 Mil).

Sonnet BioTherapeutics Holdings Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings Cash, Cash Equivalents, Marketable Securities Chart

Sonnet BioTherapeutics Holdings Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

Cash, Cash Equivalents, Marketable Securities

0.04

7.35

27.62

3.05

2.27

Sonnet BioTherapeutics Holdings Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial													11.39	7.02	2.27	3.02	3.79

Sonnet BioTherapeutics Holdings Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sonnet BioTherapeutics Holdings (NAS:SONN) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Sonnet BioTherapeutics Holdings Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540

Website

https://www.sonnetbio.com

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Executives

John Markey	10 percent owner	10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter	officer: Chief Technical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan	director, officer: Chairman, President and CEO	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney	officer: Chief Medical Officer	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg	officer: Chief Medical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini	officer: Chief Scientific Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii	officer: Chief Financial Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc	10 percent owner	918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701